Equillium to Present at H.C. Wainwright Global Life Sciences Conference
March 28, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immuno-inflammatory disorders, today announced that Dan...
Equillium Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
March 27, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe...
Equillium Announces Plan to Develop EQ001 for the Treatment of Lupus Nephritis
February 26, 2019 16:07 ET
|
Equillium
Clinical trial evaluating EQ001 for the treatment of refractory lupus nephritis to commence in 2H 2019 Ongoing EQ001 development programs in acute graft-versus-host disease and severe asthma remain...
Equillium to Host Business Update Call on February 26
February 19, 2019 16:07 ET
|
Equillium
LA JOLLA, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology company developing treatments for severe immune-inflammatory disorders, will be hosting a call with...